STEP-1 (semaglutide 2.4 mg) and medication use In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs
Gentilella R, Pechtner V, Corcos A, Consoli A
The highest retatrutide dose produced the biggest number in the Phase 3 TRIUMPH-1 trial: an average body-weight reduction of 28.3% at 80 weeks
Analysis of FAERS data from 2004 to 2020 revealed significant associations between GLP-1 RA and various neoplasms, notably medullary thyroid cancer (PRR, 27.43), papillary thyroid cancer (PRR, 8.68), malignant pancreatic neoplasms (PRR, 9.86), and pancreatic neuroendocrine neoplasms (PRR, 2.86) [52]
doi: 10.1038/s41575-019-0144-8 189 LassaillyGCaiazzoRBuobDPigeyreMVerkindtHLabreucheJet al
Curr Diabetes Rev 19:3145 Gejl M, Gjedde A, Egefjord L et al (2016) In Alzheimers disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial